All In Biotech

Drug Trial Radar · NCT04904549

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older

A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older as a Primary Series and Open-label Extension to Assess Immunogenicity, Safety, Efficacy of a Monovalent Booster Dose of SARS-CoV2 Adjuvanted Recombinant Protein Vaccine

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 23,670 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

23,670

Actual

Start

May 26, 2021

Primary completion

Aug 31, 2024

Study completion Aug 31, 2024

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
May 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a booster injection of a CoV2 preS dTM-AS03 vaccine, in adults 18 years of age and older. A total of approximately 21 046 participants are planned to be enrolled (5080 per study intervention group in Stage 1 and 5443 per study intervention group in Stage 2). Initial, double-blind, primary series study design is planned for 365 days post-last Initial injection (ie, approximately 386 days total) for each participant. Based on decisions of the Study Oversight Group, Stage 1 and Stage 2 participants will be invited to participate in an unblinded Crossover / Booster study design with duration as follows: * For participants who initially received vaccine: 12 months post-booster (ie, approximately 18 to 24 months) * For participants who initially received placebo: ≥ 4 months post-last dose of the primary series + 12 months post-booster (ie, approximately 28 to 34 months) * For participants who do not consent to continue in the unblinded Crossover / Booster part of the study, all study procedures will be stopped and participants will be discontinued from the study.

Conditions

  • COVID-19

Interventions

  • SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)Biological

    Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection

  • SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)Biological

    Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

  • PlaceboBiological

    Pharmaceutical form: liquid. Route of administration: intramuscular administration.

  • SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccinationBiological

    Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

  • SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccinationBiological

    Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1 and Stage 2: Number of Participants With Onset of Symptomatic Coronavirus Disease 2019 (COVID-19) EpisodeTime frame: From Day 36 up to Day 387
  2. Stage 1 and Stage 2: Number of Participants With Solicited Injection Site and Systemic ReactionsTime frame: Up to 7 days after each vaccination (post-dose on Days 1 and 22)
  3. Stage 1 and Stage 2: Number of Participants With Unsolicited Non-Serious Adverse Events (AEs)Time frame: Up to 21 days after each vaccination (post-dose on Days 1 and 22)
  4. Stage 1 and Stage 2: Number of Participants With Immediate Adverse EventsTime frame: Up to 30 minutes after each vaccination (post-dose on Days 1 and 22)
  5. Stage 1 and Stage 2: Number of Participants With Medically Attended Adverse Events (MAAE), Serious Adverse Events (SAE), and Adverse Events of Special Interest (AESI)Time frame: From first dose of study vaccine administration (Day 1) up to 387 days
  6. Stage 1 and Stage 2: Percentage of Participants With Virologically-Confirmed SARS-CoV-2 Infection and/or Symptomatic COVID-19Time frame: From first dose of study vaccine administration (Day 1) up to 387 days

Locations

86 sites in 11 countries. Site status is shown where the registry gives one.

  • AES - DRS - Simon Williamson Clinic, PC - Birmingham- Site Number : 8400004

    Birmingham, Alabama

  • Optimal Research Alabama- Site Number : 8400019

    Huntsville, Alabama

  • Peninsula Research Associates, Inc.- Site Number : 8400021

    Rolling Hills Estates, California

  • Synexus Clinical Research US, Inc. Site Number : 8400013

    Centennial, Colorado

  • Optimal Research, LLC-Melbourne- Site Number : 8400002

    Melbourne, Florida

  • Synexus Clinical Research US, Inc. - Orlando- Site Number : 8400020

    Orlando, Florida

  • AES St. Petersburg- Site Number : 8400017

    Pinellas Park, Florida

  • Synexus Clinical Research US, Inc. - Atlanta- Site Number : 8400005

    Atlanta, Georgia

  • Synexus Clinical Research Chicago- Site Number : 8400012

    Chicago, Illinois

  • Synexus Clinical Research Evansville- Site Number : 8400008

    Evansville, Indiana

  • Synexus St. Louis- Site Number : 8400006

    St Louis, Missouri

  • Synexus Clinical Research US, Inc. - Henderson- Site Number : 8400018

    Henderson, Nevada

  • Rochester Clinical Research, Inc.- Site Number : 8400023

    Rochester, New York

  • Synexus Akron- Site Number : 8400009

    Akron, Ohio

  • Synexus Clinical Research US, Inc. - Cincinnati- Site Number : 8400010

    Cincinnati, Ohio

  • Synexus US Columbus- Site Number : 8400011

    Columbus, Ohio

  • Synexus Clinical Research Anderson- Site Number : 8400007

    Anderson, South Carolina

  • Coastal Carolina Research Center - N Charleston- Site Number : 8400022

    North Charleston, South Carolina

  • American Indian Clinical Trials Research Network Site Number : 8400025

    Rapid City, South Dakota

  • AES Austin- Site Number : 8400003

    Austin, Texas

  • Synexus Dallas- Site Number : 8400014

    Dallas, Texas

  • Synexus Clinical Research US, Inc. - San Antonio- Site Number : 8400015

    San Antonio, Texas

  • AES Salt Lake City- Site Number : 8400016

    Murray, Utah

  • Investigational Site Number : 1700010

    Aguazul, Colombia

  • Investigational Site Number : 1700002

    Barranquilla, Colombia

  • Investigational Site Number : 1700008

    Barranquilla, Colombia

  • Investigational Site Number : 1700001

    Bogotá, Colombia

  • Investigational Site Number : 1700005

    Cali, Colombia

  • Investigational Site Number : 1700006

    Chía, Colombia

  • Investigational Site Number : 1700004

    Floridablanca, Colombia

  • Investigational Site Number : 1700007

    Girardot, Colombia

  • Investigational Site Number : 1700009

    Meta, Colombia

  • Investigational Site Number : 1700015

    Quindío, Colombia

  • Investigational Site Number : 1700003

    Soledad, Colombia

  • Investigational Site Number : 2880002

    Kintampo, Ghana

  • Investigational Site Number : 2880003

    Kumasi, Ghana

  • Investigational Site Number : 2880001

    Navrongo, Ghana

  • Investigational Site Number : 3400001

    Municipio Del Distrito Central, Honduras

  • Investigational Site Number : 3400002

    San Pedro Sula, Honduras

  • Investigational Site Number : 3560010

    Ajmer, India

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.